Smolen JS, Landewé RBM, Bijlsma JWJ, et al. - Researchers explored an update of the European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) management recommendations to account for the most recent developments in the field. These updated EULAR recommendations provide consensus on the management of RA with respect to benefit, safety, preferences and cost. An international task force recognized new proof supporting or contradicting previous suggestions and novel therapies and strategic insights based on two systematic literature explorations on efficacy and safety of disease-modifying antirheumatic drugs (DMARDs) between 2016 and 2019. They used predefined voting process, selected current levels of evidence and strengths of recommendation and participants ultimately voted independently on their level of agreement with each of the items. The results suggested that this updated EULAR guidance gives consensus on the management of RA with respect to benefit, safety, preferences and cost.